Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Dose Escalation Study to Assess the Efficacy and Safety of Bradanicline in Subjects With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, crossover, dose escalation study of bradanicline in subjects with chronic cough
100 Clinical Results associated with Attenua, Inc.
0 Patents (Medical) associated with Attenua, Inc.
100 Deals associated with Attenua, Inc.
100 Translational Medicine associated with Attenua, Inc.